Home › Companies › Tyra Biosciences, Inc. › 2025-2026
At Tyra Biosciences, Inc.'s shareholder meeting held May 28, 2026, in the 2025-2026 proxy season, 51 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 705 separate fund positions. On the most widely held item on that ballot — To elect three directors to serve as Class II directors for a three-year term expiring at the… — FOR was 99% of the votes cast (FOR divided by FOR plus WITHHELD, because this ballot offered only for and withhold; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Tyra Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 2, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Tyra Biosciences, Inc.’s Form 8-K, filed June 2, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of May 28, 2026: 4 items on Tyra Biosciences, Inc.’s Form 8-K, filed June 2, 2026: 1 approved · 3 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2025-2026
Explore Tyra Biosciences, Inc. in the interactive database Compare manager voting policies
These tallies are Tyra Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 2, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Habib J. Dable | 44,242,803 | -- | -- | 476,602 | 8,377,977 | 99% | Not verified | — |
| Elect Director: Susan Moran, M.D., M.S.C.E. | 44,529,688 | -- | -- | 189,717 | 8,377,977 | 99.5% | Not verified | — |
| Elect Director: Robert More | 41,013,686 | -- | -- | 3,705,719 | 8,377,977 | 92% | Not verified | — |
| 2. The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The appointment | 53,092,820 | 1,316 | 3,246 | -- | -- | 99.9% | Approved | — |
Source: Tyra Biosciences, Inc., Form 8-K, filed with the SEC on June 2, 2026 — read the filing on EDGAR.
Each item below shows how the 51 asset managers that disclosed a Tyra Biosciences, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Habib J. Dable
Tyra Biosciences, Inc.’s own tally for this item (“Elect Director: Habib J. Dable”): 44,242,803 for, 476,602 withheld, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 12,156,313 for, 50,983 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,642,591 | 0 | 0 | 0 | For |
| Vanguard | 1,358,945 | 0 | 0 | 0 | For |
| T. Rowe Price | 720,835 | 0 | 0 | 0 | For |
| State Street | 622,798 | 0 | 0 | 25 | For |
| JANUS INVESTMENT FUND | 555,567 | 0 | 0 | 0 | For |
| BlackRock | 288,149 | 0 | 0 | 0 | For |
| Charles Schwab | 199,072 | 0 | 0 | 0 | For |
| Prudential/PGIM | 182,879 | 0 | 0 | 1,770 | For |
| Equitable | 47,369 | 0 | 0 | 19,930 | Mixed |
| American Century | 47,929 | 0 | 0 | 0 | For |
| TIAA | 47,609 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 44,460 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 43,856 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 41,730 | 0 | 0 | 0 | For |
| Nationwide | 32,854 | 0 | 0 | 0 | For |
| Lincoln Financial | 32,755 | 0 | 0 | 0 | For |
| Russell Investments | 31,119 | 0 | 0 | 0 | For |
| Brighthouse | 28,240 | 0 | 0 | 0 | For |
| ProShares | 21,773 | 0 | 0 | 0 | For |
| JPMorgan | 19,256 | 0 | 0 | 0 | For |
| Franklin Alternative Strategies Funds | 16,871 | 0 | 0 | 0 | For |
| Putnam | 16,871 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 16,562 | Withhold |
| John Hancock | 14,173 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 13,681 | 0 | 0 | 0 | For |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Robert More
Tyra Biosciences, Inc.’s own tally for this item (“Elect Director: Robert More”): 41,013,686 for, 3,705,719 withheld, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 11,322,153 for, 885,140 withheld, 2 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,642,591 | 0 | 0 | 0 | For |
| Vanguard | 1,358,048 | 0 | 2 | 895 | For |
| T. Rowe Price | 720,835 | 0 | 0 | 0 | For |
| State Street | 1,312 | 0 | 0 | 621,511 | Withhold |
| JANUS INVESTMENT FUND | 555,567 | 0 | 0 | 0 | For |
| BlackRock | 288,149 | 0 | 0 | 0 | For |
| Charles Schwab | 199,072 | 0 | 0 | 0 | For |
| Prudential/PGIM | 182,879 | 0 | 0 | 1,770 | For |
| Equitable | 47,369 | 0 | 0 | 19,930 | Mixed |
| American Century | 0 | 0 | 0 | 47,929 | Withhold |
| TIAA | 47,609 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 44,460 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 0 | 0 | 0 | 43,856 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 41,730 | 0 | 0 | 0 | For |
| Nationwide | 1,154 | 0 | 0 | 31,700 | Withhold |
| Lincoln Financial | 4,385 | 0 | 0 | 28,370 | Mixed |
| Russell Investments | 31,119 | 0 | 0 | 0 | For |
| Brighthouse | 19,200 | 0 | 0 | 9,040 | Mixed |
| ProShares | 0 | 0 | 0 | 21,773 | Withhold |
| JPMorgan | 19,256 | 0 | 0 | 0 | For |
| Franklin Alternative Strategies Funds | 16,871 | 0 | 0 | 0 | For |
| Putnam | 16,871 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 16,562 | Withhold |
| John Hancock | 6,900 | 0 | 0 | 7,273 | Mixed |
| AIG/SunAmerica | 0 | 0 | 0 | 13,681 | Withhold |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
Description as filed by funds: To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified: Susan Moran, M.D., M.S.C.E.
Tyra Biosciences, Inc.’s own tally for this item (“Elect Director: Susan Moran, M.D., M.S.C.E.”): 44,529,688 for, 189,717 withheld, per its Form 8-K filed June 2, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.5% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 12,183,027 for, 24,269 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,642,591 | 0 | 0 | 0 | For |
| Vanguard | 1,358,945 | 0 | 0 | 0 | For |
| T. Rowe Price | 720,835 | 0 | 0 | 0 | For |
| State Street | 622,823 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 555,567 | 0 | 0 | 0 | For |
| BlackRock | 288,149 | 0 | 0 | 0 | For |
| Charles Schwab | 199,072 | 0 | 0 | 0 | For |
| Prudential/PGIM | 182,879 | 0 | 0 | 1,770 | For |
| Equitable | 47,369 | 0 | 0 | 19,930 | Mixed |
| American Century | 47,929 | 0 | 0 | 0 | For |
| TIAA | 47,609 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 44,460 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 43,856 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 41,730 | 0 | 0 | 0 | For |
| Nationwide | 32,854 | 0 | 0 | 0 | For |
| Lincoln Financial | 32,755 | 0 | 0 | 0 | For |
| Russell Investments | 31,119 | 0 | 0 | 0 | For |
| Brighthouse | 28,240 | 0 | 0 | 0 | For |
| ProShares | 21,773 | 0 | 0 | 0 | For |
| JPMorgan | 19,256 | 0 | 0 | 0 | For |
| Franklin Alternative Strategies Funds | 16,871 | 0 | 0 | 0 | For |
| Putnam | 16,871 | 0 | 0 | 0 | For |
| Northern Trust | 16,562 | 0 | 0 | 0 | For |
| John Hancock | 14,173 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 13,681 | 0 | 0 | 0 | For |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.
Tyra Biosciences, Inc.’s own tally for this item (“2. The ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The appointment”): 53,092,820 for, 1,316 against — passed, per its Form 8-K filed June 2, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The appointment was ratified by the votes indicated:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 51 asset managers below reported 12,207,296 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,642,591 | 0 | 0 | 0 | For |
| Vanguard | 1,358,945 | 0 | 0 | 0 | For |
| T. Rowe Price | 720,835 | 0 | 0 | 0 | For |
| State Street | 622,823 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 555,567 | 0 | 0 | 0 | For |
| BlackRock | 288,149 | 0 | 0 | 0 | For |
| Charles Schwab | 199,072 | 0 | 0 | 0 | For |
| Prudential/PGIM | 184,649 | 0 | 0 | 0 | For |
| Equitable | 67,299 | 0 | 0 | 0 | For |
| American Century | 47,929 | 0 | 0 | 0 | For |
| TIAA | 47,609 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 44,460 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 43,856 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 41,730 | 0 | 0 | 0 | For |
| Nationwide | 32,854 | 0 | 0 | 0 | For |
| Lincoln Financial | 32,755 | 0 | 0 | 0 | For |
| Russell Investments | 31,119 | 0 | 0 | 0 | For |
| Brighthouse | 28,240 | 0 | 0 | 0 | For |
| ProShares | 21,773 | 0 | 0 | 0 | For |
| JPMorgan | 19,256 | 0 | 0 | 0 | For |
| Franklin Alternative Strategies Funds | 16,871 | 0 | 0 | 0 | For |
| Putnam | 16,871 | 0 | 0 | 0 | For |
| Northern Trust | 16,562 | 0 | 0 | 0 | For |
| John Hancock | 14,173 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 13,681 | 0 | 0 | 0 | For |
Showing the 25 largest of 51 asset managers. All 51 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 59,470,381 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 12.85% |
| 2 | Vanguard | 2.29% |
| 3 | T. Rowe Price | 1.21% |
| 4 | State Street | 1.05% |
| 5 | JANUS INVESTMENT FUND | 0.93% |
| 6 | BlackRock | 0.48% |
| 7 | Charles Schwab | 0.33% |
| 8 | Prudential/PGIM | 0.31% |
| 9 | Equitable | 0.11% |
| 10 | American Century | 0.08% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| RA Capital Management, L.P. | 23.76% | 13D |
| FMR (Fidelity) | 13.03% | 13F |
| FMR LLC | 13.03% | 13G |
| BVF PARTNERS L P/IL | 7.09% | 13G |
| JANUS HENDERSON GROUP PLC | 6.54% | 13G |
| Nextech VI Oncology SCSp | 5.98% | 13G |
| Paradigm BioCapital Advisors LP | 5.84% | 13G |
| Dapice Joshua J. | 5.02% | 13G |
| Todd Harris | 4.90% | 13G |
| Commodore Capital LP | 4.16% | 13G |
Percentages above are of 59,470,381 shares outstanding, as reported by Tyra Biosciences, Inc. on its Form 10-Q dated May 8, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Tyra Biosciences, Inc.’s 10-Q dated May 8, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Tyra Biosciences, Inc. proxy season coverage: 2025-2026 (this page).
proxyvotesnow.com, “Tyra Biosciences (TYRA) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/tyra-biosciences-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.